{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:49:36Z","timestamp":1792046976691,"version":"4.4.0"},"reference-count":44,"publisher":"American Association for Cancer Research (AACR)","issue":"10","license":[{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031949","name":"Guardant Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Despite recent adoption of perioperative therapy for high-risk melanoma, its overall survival (OS) benefit remains unclear, highlighting the need for biomarkers to identify patients likely to benefit from treatment. Detection of circulating tumor DNA (ctDNA) after definitive treatment predicts recurrence, and emerging molecular residual disease (MRD) assays may influence management. We validated a tissue-free MRD assay in 48 patients with clinical stage II to III melanoma treated with surgery (52% nonacral cutaneous, 31% acral, and 17% mucosal). The assay detects MRD through bioinformatic analysis of methylation signals across &amp;gt;20,000 epigenomic regions. Plasma samples (n = 281; 280 successfully reported) were prospectively collected before surgery, at day 28, and every 3 to 6 months thereafter. Associations among MRD detection, recurrence, and OS were analyzed. At a median follow-up of 34.6 months with 27 recurrence events, postoperative surveillance sensitivity for distant recurrence was 81% with 100% posttreatment specificity. The median lead time between MRD detection and radiographic recurrence was 70.5 days. Surveillance MRD detection was associated with increased recurrence risk [hazard ratio (HR), 26.55; 95% confidence interval (CI), 2.86\u2013246.58; P = 0.004]. Similarly, MRD detection 28 days postoperatively independently predicted recurrence (HR, 11.70; 95% CI, 3.09\u201343.76; P &amp;lt; 0.001) and death (HR, 31.14; 95% CI, 5.37\u2013221.1; P &amp;lt; 0.001). Tissue-free epigenomic MRD detection was sensitive, specific, and significantly associated with recurrence and melanoma-related death. These findings support the use of this assay in melanoma as a rapid, noninvasive approach for earlier identification of patients at high risk for recurrence, enabling refined treatment and surveillance strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Prognostic tools for high-risk melanoma rely on baseline factors with limited dynamic risk assessment. A tissue-free MRD assay demonstrated high sensitivity and specificity for distant recurrence detection, identifying molecular relapse before radiographic recurrence. Postoperative MRD detection was strongly associated with recurrence and melanoma-related death, enabling refined treatment and surveillance strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0388","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T14:32:40Z","timestamp":1791210760000},"page":"2412-2421","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Melanoma Recurrence Prediction Using a Tissue-Free Epigenomic Molecular Residual Disease Assay: A Multicenter Prospective Observational Study (COSMOS-MEL01)"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2763-7346","authenticated-orcid":false,"given":"Kenjiro","family":"Namikawa","sequence":"first","affiliation":[{"name":"1Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1335-7100","authenticated-orcid":false,"given":"Dai","family":"Ogata","sequence":"additional","affiliation":[{"name":"1Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7632-8182","authenticated-orcid":false,"given":"Eiji","family":"Nakano","sequence":"additional","affiliation":[{"name":"1Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-0428","authenticated-orcid":false,"given":"Naoya","family":"Yamazaki","sequence":"additional","affiliation":[{"name":"1Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1462-9211","authenticated-orcid":false,"given":"Azusa","family":"Komada","sequence":"additional","affiliation":[{"name":"2Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9304-7590","authenticated-orcid":false,"given":"Akira","family":"Takahashi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 3 Department of Dermatologic Oncology, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6082-4696","authenticated-orcid":false,"given":"Shusuke","family":"Yoshikawa","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/0042ytd14","id-type":"ROR","asserted-by":"publisher"}],"name":"Shizuoka Cancer Center 4 Department of Dermatology, , Shizuoka, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1998-7650","authenticated-orcid":false,"given":"Chiemi","family":"Notake","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 5 Translational Research Support Office, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2132-1232","authenticated-orcid":false,"given":"Ryuta","family":"Mitani","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 5 Translational Research Support Office, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0489-4756","authenticated-orcid":false,"given":"Takayuki","family":"Yoshino","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 6 Department of Gastroenterology and Gastrointestinal Oncology, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-6855","authenticated-orcid":false,"given":"Yoshiaki","family":"Nakamura","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03rm3gk43","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Center Hospital East 5 Translational Research Support Office, , Kashiwa, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,10,15]]},"reference":[{"key":"2026101502373321800_bib1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026101502373321800_bib2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/cancers17040707","article-title":"Clinical approaches for the management of skin cancer: a review of current progress in diagnosis, treatment, and prognosis for patients with melanoma","volume":"17","author":"Connor","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026101502373321800_bib3","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40257-024-00852-5","article-title":"Rapidly evolving pre- and post-surgical systemic treatment of melanoma","volume":"25","author":"Augustin","year":"2024","journal-title":"Am J Clin Dermatol"},{"key":"2026101502373321800_bib4","article-title":"Cutaneous melanoma (NCCN Clinical Practice Guidelines in Oncology). Version 2.2025","author":"National Comprehensive Cancer Network","year":"2025"},{"key":"2026101502373321800_bib5","doi-asserted-by":"publisher","first-page":"e666","DOI":"10.1111\/1346-8138.17740","article-title":"Japanese Dermatological Association guidelines: clinical questions of guidelines for melanoma 2025","volume":"52","author":"Fukushima","year":"2025","journal-title":"J Dermatol"},{"key":"2026101502373321800_bib6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.annonc.2024.11.006","article-title":"Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Amaral","year":"2025","journal-title":"Ann Oncol"},{"key":"2026101502373321800_bib7","doi-asserted-by":"publisher","first-page":"115153","DOI":"10.1016\/j.ejca.2024.115153","article-title":"European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment - update 2024","volume":"215","author":"Garbe","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026101502373321800_bib8","first-page":"207","article-title":"Melanoma radiological surveillance: a review of current evidence and clinical challenges","volume":"93","author":"Howard","year":"2020","journal-title":"Yale J Biol Med"},{"key":"2026101502373321800_bib9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.soc.2014.12.012","article-title":"Long-term follow-up for melanoma patients: is there any evidence of a benefit?","volume":"24","author":"Rueth","year":"2015","journal-title":"Surg Oncol Clin N Am"},{"key":"2026101502373321800_bib10","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1056\/NEJMra072149","article-title":"Computed tomography\u2013an increasing source of radiation exposure","volume":"357","author":"Brenner","year":"2007","journal-title":"N Engl J Med"},{"key":"2026101502373321800_bib11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/jnci\/djq455","article-title":"Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis","volume":"103","author":"Xing","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2026101502373321800_bib12","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s10147-024-02683-0","article-title":"Japan Society of Clinical Oncology position paper on appropriate clinical use of molecular residual disease (MRD) testing","volume":"30","author":"Kobayashi","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"2026101502373321800_bib13","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/annonc\/mdz048","article-title":"Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA","volume":"30","author":"Tan","year":"2019","journal-title":"Ann Oncol"},{"key":"2026101502373321800_bib14","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1158\/1078-0432.CCR-25-3643","article-title":"Longitudinal ctDNA monitoring for postsurgical disease surveillance in patients with stage I to IIIB melanoma","volume":"32","author":"Ansstas","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026101502373321800_bib15","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1093\/annonc\/mdx717","article-title":"Circulating tumor DNA predicts survival in patients with resected high-risk stage II\/III melanoma","volume":"29","author":"Lee","year":"2018","journal-title":"Ann Oncol"},{"key":"2026101502373321800_bib16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/PO.19.00174","article-title":"Circulating tumor DNA allows early treatment monitoring in BRAF- and NRAS-mutant malignant melanoma","volume":"4","author":"Braune","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"2026101502373321800_bib17","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1470-2045(25)00139-1","article-title":"Clinical validation of droplet digital PCR assays in detecting BRAFV600-mutant circulating tumour DNA as a prognostic biomarker in patients with resected stage III melanoma receiving adjuvant therapy (COMBI-AD): a biomarker analysis from a double-blind, randomised phase 3 trial","volume":"26","author":"Syeda","year":"2025","journal-title":"Lancet Oncol"},{"key":"2026101502373321800_bib18","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.ctrv.2024.102788","article-title":"Circulating tumor DNA-based assessment of molecular residual disease in non-metastatic melanoma","volume":"129","author":"De Simoni","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"2026101502373321800_bib19","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1186\/s12967-024-05783-7","article-title":"Monitoring circulating tumor DNA liquid biopsy in stage III BRAF-mutant melanoma patients undergoing adjuvant treatment","volume":"22","author":"Marchisio","year":"2024","journal-title":"J Transl Med"},{"key":"2026101502373321800_bib20","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1158\/1078-0432.CCR-24-1651","article-title":"Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay","volume":"30","author":"Nakamura","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026101502373321800_bib21","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1200\/JCO-25-02086","article-title":"Tissue-free circulating tumor DNA assay and patient outcome in a phase III trial of FOLFOX-based adjuvant chemotherapy (Alliance N0147)","volume":"44","author":"Sinicrope","year":"2026","journal-title":"J Clin Oncol"},{"key":"2026101502373321800_bib22","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1158\/1078-0432.CCR-25-2958","article-title":"Minimal residual disease enhances prognostic stratification beyond pathologic response in resectable non-small cell lung cancer","volume":"32","author":"Provencio","year":"2026","journal-title":"Clin Cancer Res"},{"key":"2026101502373321800_bib23","doi-asserted-by":"publisher","first-page":"105286","DOI":"10.1016\/j.esmoop.2025.105286","article-title":"Comprehensive tumor-agnostic evaluation of genomic and epigenomic-based approaches for the identification of circulating tumor DNA in early-stage breast cancer","volume":"10","author":"Elliott","year":"2025","journal-title":"ESMO Open"},{"key":"2026101502373321800_bib24","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1158\/1078-0432.CCR-24-3145","article-title":"Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple-negative breast cancer","volume":"31","author":"Ademuyiwa","year":"2025","journal-title":"Clin Cancer Res"},{"key":"2026101502373321800_bib25","doi-asserted-by":"publisher","first-page":"115782","DOI":"10.1016\/j.ejca.2025.115782","article-title":"A dynamic recurrence risk prediction tool for adjuvant therapy in stage III melanoma","volume":"229","author":"Boutros","year":"2025","journal-title":"Eur J Cancer"},{"key":"2026101502373321800_bib26","doi-asserted-by":"publisher","first-page":"116676","DOI":"10.1016\/j.ejca.2026.116676","article-title":"Translating ctDNA into cutaneous melanoma care: an international expert survey","volume":"239","author":"Geidel","year":"2026","journal-title":"Eur J Cancer"},{"key":"2026101502373321800_bib27","doi-asserted-by":"publisher","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2026101502373321800_bib28","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.tranon.2024.101883","article-title":"Corresponding ctDNA and tumor burden dynamics in metastatic melanoma patients on systemic treatment","volume":"42","author":"Egger","year":"2024","journal-title":"Transl Oncol"},{"key":"2026101502373321800_bib29","doi-asserted-by":"publisher","first-page":"4748","DOI":"10.1111\/cas.15088","article-title":"Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma","volume":"112","author":"Takai","year":"2021","journal-title":"Cancer Sci"},{"key":"2026101502373321800_bib30","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.3390\/cancers17233804","article-title":"Personalized circulating tumor DNA assay to assess long-term clinical benefit in patients with advanced melanoma","volume":"17","author":"Mart\u00ednez-Vila","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026101502373321800_bib31","doi-asserted-by":"publisher","first-page":"3054","DOI":"10.3390\/diagnostics15233054","article-title":"Toward personalized response monitoring in melanoma patients treated with immunotherapy and target therapy","volume":"15","author":"Venturi","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"2026101502373321800_bib32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_351153","article-title":"Current state of adjuvant therapy for melanoma: less is more, or more is better?","volume":"42","author":"Lao","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2026101502373321800_bib33","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/biomedicines13081894","article-title":"Adjuvant immunotherapy in stage IIB\/IIC melanoma: current evidence and future directions","volume":"13","author":"Prka\u010din","year":"2025","journal-title":"Biomedicines"},{"key":"2026101502373321800_bib34","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"},{"key":"2026101502373321800_bib35","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"2026101502373321800_bib36","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1016\/j.jlb.2025.100295","article-title":"Circulating tumor DNA monitoring in advanced mutated melanoma (LIQUID-MEL)","volume":"8","author":"Gianmarco","year":"2025","journal-title":"J Liq Biopsy"},{"key":"2026101502373321800_bib37","doi-asserted-by":"publisher","first-page":"3913","DOI":"10.3390\/cancers13153913","article-title":"Plasma BRAF mutation detection for the diagnostic and monitoring trajectory of patients with LDH-high stage IV melanoma","volume":"13","author":"Tolmeijer","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026101502373321800_bib38","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12967-016-0852-6","article-title":"Quantitative assessment of BRAF V600 mutant circulating cell-free tumor DNA as a tool for therapeutic monitoring in metastatic melanoma patients treated with BRAF\/MEK inhibitors","volume":"14","author":"Schreuer","year":"2016","journal-title":"J Transl Med"},{"key":"2026101502373321800_bib39","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1002\/cncr.34716","article-title":"Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients","volume":"129","author":"Eroglu","year":"2023","journal-title":"Cancer"},{"key":"2026101502373321800_bib40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.16.00009","article-title":"Circulating tumor DNA analysis and functional imaging provide complementary approaches for comprehensive disease monitoring in metastatic melanoma","volume":"1","author":"Wong","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"2026101502373321800_bib41","doi-asserted-by":"publisher","first-page":"6850","DOI":"10.1038\/s41467-026-72735-8","article-title":"Use of circulating tumour DNA to prospectively guide a switch from targeted to immune therapy in BRAF mutant advanced melanoma: the randomised phase II CAcTUS trial","volume":"17","author":"Lee","year":"2026","journal-title":"Nat Commun"},{"key":"2026101502373321800_bib42","doi-asserted-by":"publisher","first-page":"103146","DOI":"10.1016\/j.ctrv.2026.103146","article-title":"Circulating tumor DNA for predicting recurrence and mortality in patients with resected melanoma: a systematic review and meta-analysis","volume":"147","author":"Reis","year":"2026","journal-title":"Cancer Treat Rev"},{"key":"2026101502373321800_bib43","doi-asserted-by":"publisher","first-page":"100585","DOI":"10.1016\/j.ejcskn.2025.100585","article-title":"DETECTION-2 feasibility: a phase 2 trial comparing adjuvant therapy to ctDNA follow-up in resected stage IIB\/IIC\/IIIA melanoma","volume":"3","author":"Lee","year":"2025","journal-title":"EJC Skin Cancer"},{"key":"2026101502373321800_bib44","doi-asserted-by":"publisher","first-page":"S306","DOI":"10.1016\/j.annonc.2024.08.2230","article-title":"226TiP CLEAR-Me: interception trial to detect and clear molecular residual disease in patients with high-risk melanoma","volume":"35","author":"Saldanha","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0388\/3835647\/crc-26-0388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2412\/3839540\/crc-26-0388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/10\/2412\/3839540\/crc-26-0388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:37:44Z","timestamp":1792046264000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/10\/2412\/789415\/Melanoma-Recurrence-Prediction-Using-a-Tissue-Free"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":44,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0388","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.34518807","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518789","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518777","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518798","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518786","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518810","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518801","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518804","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518774","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518795","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518783","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518771","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518792","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.34518780","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8775120","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]}}}